RPG Life Sciences Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/as-dd76aa5e233255ad966d6ea9.pdf

Key Takeaways


The API Platform Build

Ashok Nair: "We believe that by combining Ragwa's product and capacity with AKPI's backward integration possibilities, RPG's existing API business systems, processes and governance framework along with our PE partner sector expertise, we can unlock substantially more value than either asset could achieve independently."

The Acquired Assets: Actis and Raghava

Operator: "The decline in Actis was not due to any structural issue with the business. In fact the product portfolio or the manufacturing asset. The company continued to maintain strong customer relationship, technical capabilities and highly utilized facility. Our assessment actually indicated that the business had limited access to growth capital and a broader commercialization engine which constrained its ability to fully capitalize on the operational available in the market."

Domestic Formulation: The Steady Engine


Capital Deployment and Financial Commitments

Operator: "We would like to be disciplined as far as the capital allocation is concerned."

Margin Trajectory and Near-Term Pressure


Unanswered Questions


Guidance & Commitments

CommitmentSpecificsTimeline
API business growth25%+ growth CAGR through organic and inorganic interventionsSustaining over next 5 years
Consolidated API CAGR20%+ CAGR for the consolidated API businessNext 3–4 years on a sustained basis
API revenue aspiration₹1,000 crore in the API business5–6 years
API revenue milestoneCross ₹200 crores revenue markApproximately 2 years
Fund deployment₹700 crore total commitment deployed for acquisitions and capacityNext 12–15 months
Formulation growthGrow 1.5x more than the marketOngoing
API marginsMid-20s on a sustainable basis, with pressure in the initial period post-acquisitionPost initial acquisition pressure period
Captive salesRemain in similar range as last year (~₹15 crores)Annual

Key Metrics

MetricQ1 FY27
Revenue₹95.1 cr (API external third-party sales in FY26)
Domestic formulation revenue share70% of total revenue
International formulation revenue share14% of total revenue
Domestic formulation growth16% in FY26, vs 12% over prior 3–4 years
Domestic formulation growth vs market1.3–1.8x the market over the last five quarters
IPM rank15 in June 2026, up from 62 in March 2025 (12-rank improvement)
IPM growth ranking5th fastest growing pharma company in India (per Match Pharma Prime June 2026)
API business EBITDA marginMid-20s (management declined to disclose exact figure); expected to remain at similar level with acquisitions
API business growth target20%+ CAGR on a sustained basis over next 3–4 years; ~25% over next 3–5 years
API business long-term revenue aspiration₹1,000 cr, to be reached in 5–6 years
Combined API installed capacity~505 kg, more than fourfold increase from ~110 kg previously
API employee strengthOver 500, up from about 217
API R&D scientist team53, up from 28
API product portfolio45+ products across 13 therapies, up from 14 products across 6 therapies
API customer baseOver 250, up from 123
API pipeline molecules28, up from 12
Actis Generics acquisition consideration~₹80 cr including net working capital
Raghava Life Sciences acquisition considerationUp to ₹135 cr including net working capital
Raghava revenue potential at fuller utilization~₹200 cr, expected to be crossed in approximately two years
Raghava current international revenue share15–20%, rest domestic
Total planned API investment₹700 cr, with ~₹240 cr already committed for Actis and Raghava; balance to be deployed in 12–18 months
Invascent stake in RPG Active Pharma40% on a fully diluted basis
Annual captive API sales to RPG Life Sciences~₹15 cr in FY26, expected in similar range
Consolidated entity cash position₹200 cr plus